Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study
Open Access
- 7 May 2002
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (9) , 1401-1410
- https://doi.org/10.1038/sj.bjc.6600198
Abstract
Antibody engineering has made it possible to design antibodies with optimal characteristics for delivery of radionuclides for tumour imaging and therapy. A humanised divalent-Fab' cross-linked with a bis-maleimide linker referred to as humanised divalent-Fab' maleimide was produced as a result of this design process. It is a humanised divalent antibody with no Fc, which can be produced in bacteria and has enhanced stability compared with F(ab')(2). Here we describe a clinical study in patients with colorectal cancer using humanised divalent-Fab' maleimide generated from the anti-carcinoembryonic antigen antibody A5B7 radiolabelled with iodine-131. Ten patients received an i.v. injection of iodine-131-labelled A5B7 humanised divalent-Fab' maleimide, and positive tumour images were obtained by gamma camera imaging in eight patients with known lesions, and one previously undetected lesion was identified. True negative results were obtained in two patients without tumour. Area under the curve analysis of serial blood gamma counting and gamma camera images showed a higher tumour to blood ratio compared to A5B7 mF(ab')(2) used previously in the clinic, implying this new molecule may be superior for radioimmunotherapy. MIRD dose calculations showed a relatively high radiation dose to the kidney, which may limit the amount of activity that could be administered in radioimmunotherapy. However the reduction in immunogenicity was also a major advantage for A5B7 humanised divalent-Fab' maleimide over murine versions of this antibody suggesting that humanised divalent-Fab' maleimide should be a useful vehicle for repeated therapies.Keywords
This publication has 25 references indexed in Scilit:
- Late renal function following whole abdominal irradiationRadiotherapy and Oncology, 1996
- Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatographyJournal of Immunological Methods, 1995
- Circulating antigen: Bad or good for immunoscintigraphy?Nuclear Medicine and Biology, 1995
- Making Antibodies by Phage Display TechnologyAnnual Review of Immunology, 1994
- Antigen-specific human antibodies from mice comprising four distinct genetic modificationsNature, 1994
- Section Review: Humanised monoclonal antibodies for therapeutic applicationsExpert Opinion on Investigational Drugs, 1994
- Cancer research campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trialsEuropean Journal Of Cancer, 1993
- REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1HThe Lancet, 1988
- Reshaping Human Antibodies: Grafting an Antilysozyme ActivityScience, 1988
- The use of radionuclides for tumor therapyInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1986